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SUMMARY: 31 
This method describes a robust and reproducible approach for the comparison of protein levels 32 
in different tissues and at different developmental timepoints using a standardized quantitative 33 
western blotting approach.   34 
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ABSTRACT: 35 
Western blotting is a technique that is commonly used to detect and quantify protein 36 
expression. Over the years, this technique has led to many advances in both basic and clinical 37 
research. However, as with many similar experimental techniques, the outcome of western blot 38 
analyses is easily influenced by choices made in the design and execution of the experiment. 39 
Specific housekeeping proteins have traditionally been used to normalize protein levels for 40 
quantification, however, these have a number of limitations and have therefore been 41 
increasingly criticized over the past few years. Here, we describe a detailed protocol that we 42 
have developed to allow us to undertake complex comparisons of protein expression variation 43 
across different tissues, mouse models (including disease models), and developmental 44 
timepoints. By using a fluorescent total protein stain and introducing the use of an internal 45 
loading standard it is possible to overcome existing limitations in the number of samples that 46 
can be compared within experiments and systematically compare protein levels across a range 47 
of experimental conditions. This approach expands the use of traditional western blot 48 
techniques, thereby allowing researchers to better explore protein expression across different 49 
tissues and samples.  50 
 51 
INTRODUCTION: 52 
Western blotting is a technique that is commonly used to detect and quantify protein 53 
expression, including in tissue homogenates or extracts. Over the years, this technique has led 54 
to many advances in both basic and clinical research, where it can be used as a diagnostic tool 55 
to identify the presence of disease1,2. Western blotting was first described in 1979 as a method 56 
to transfer proteins from polyacrylamide gels to nitrocellulose sheets and subsequently 57 
visualize proteins using secondary antibodies that were either radioactively labelled or 58 
conjugated to fluorescein or peroxidase3. Through the development of commercially available 59 
kits and equipment, western blotting methods have been increasingly standardized and 60 
simplified over the years. Indeed, the technique is now readily performed by scientists with 61 
varying backgrounds and levels of experience. However, as with many similar experimental 62 
techniques, the outcome of western blot analyses is easily influenced by choices made in the 63 
design and execution of the experiment. It is important, therefore, that the accessibility of 64 
standardized western blotting methods does not obscure the need for careful experimental 65 
planning and design. Experimental considerations include, but are not limited to, sample 66 
preparation and handling, selection and validation of antibodies for protein detection, and gel-67 
to-membrane transfer efficiency of particularly small or large (<10 or >140 kDa) proteins4-9. 68 
Protein quality of the original sample plays a significant role in determining the outcome of the 69 
subsequent western blot analysis. As protein can be extracted from a wide variety of samples 70 
and sources, including cell lines, tissues from animal models, and post-mortem human tissues, 71 
consistency in handling and processing is required to obtain reproducible results. For example, 72 
   
Page 2 of 13   
 
when long-term storage of samples for protein extraction is required, it is important to realize 73 
that, although protein is generally stable at -80°C, differences in protein stability between 74 
extracted proteins and intact tissues at -80°C have been reported10. Moreover, to obtain 75 
reproducible estimates of protein quantities, consistent homogenization of samples is crucial. 76 
Optimizing different lysis buffers and homogenization methods (e.g. manual homogenization 77 
compared to automated methods) may be required before starting a large-scale quantitative 78 
experiment.  79 
Normalization strategies to correct for protein loading and quantification variability are 80 
essential to obtain robust, quantitative results of protein expression. Housekeeping proteins 81 
such as ß-actin, α-tubulin, ß-tubulin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 82 
have traditionally been used to normalize protein levels for quantification. However, 83 
normalization to specific housekeeping proteins for quantification purposes has been 84 
increasingly criticized over the past few years11,12. For example, the expression of housekeeping 85 
proteins can change across different developmental stages13,14, across tissues from the same 86 
animal4, and under various disease conditions4,15-17. Therefore, the use of specific housekeeping 87 
proteins limits the possibilities of making more complex comparisons between protein 88 
expression from different tissues, at different timepoints and under varying experimental 89 
conditions. An alternative to housekeeping proteins to control for protein loading variation is 90 
the use of a total protein stain (TPS) that labels and visualizes all proteins present in a sample. 91 
TPS allows signal normalization based on total protein load rather than levels of one specific 92 
protein and therefore quantification of TPS signal should be comparable and reproducible 93 
regardless of experimental condition, sample type or developmental timepoint. Examples of 94 
total protein stains include Ponceau S, stain-free gels, Coomassie R-350, Sypro-Ruby, 95 
Epicocconone, Amydo Black, and Cy5 (reviewed in ref. 18). Each of these methods has specific 96 
advantages and limitations and method selection depends on the time and tools available as 97 
well as the experimental setup4,18.  98 
In addition to using a TPS to correct for within-membrane loading and quantification 99 
variability, it may be necessary to compare samples between different membranes, particularly 100 
when performing large-scale protein expression analysis. However, variability in factors such as 101 
antibody binding efficiency and total protein stain intensity may introduce further variability 102 
between protein samples that are analyzed on separate gels and membranes. For robust 103 
quantification in this situation it is therefore necessary to introduce a further normalization 104 
step to account for between-membrane variability. This can be achieved by including an 105 
internal loading standard on each of the separately analyzed membranes that is kept constant 106 
across experiments. This standard can take the form of any protein lysate that can be obtained 107 
in sufficient quantities to be used across all membranes included in the experiment. Here we 108 
use a lysate of mouse brain (obtained from 5 day old control mice), as brain is readily 109 
homogenized and the obtained protein lysate contains a significant amount of protein at a high 110 
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concentration. Loading an internal standard in triplicate allows samples on separate 111 
membranes to be normalized and compared directly.  112 
Here, we describe a detailed protocol that we have developed to allow us to undertake 113 
complex comparisons of protein expression variation across different tissues, mouse models 114 
(including disease models), and developmental timepoints19. By combining a fluorescent TPS 115 
with the use of an internal loading standard we were able to overcome existing limitations in 116 
the number of samples and experimental conditions that can be compared within a single 117 
experiment. This approach expands the use of traditional western blot techniques, thereby 118 
allowing researchers to better explore protein expression across different tissues and samples.  119 
 120 
PROTOCOL: 121 
This protocol has been optimized using standardized, commercially available kits and reagents 122 
in order to increase reproducibility (see Table of Materials). 123 
 124 
Ethics Statement: 125 
Tissues for this procedure were obtained from animal studies that were approved by the 126 
internal ethics committee at the University of Edinburgh and were performed in concordance 127 
with institutional and UK Home Office regulations under the authority of relevant personal and 128 
project licenses. 129 
 130 
1. Preparation of samples 131 
1.1. Protein extraction  132 
1.1.1. Transfer snap-frozen cell or tissue samples from -80°C on dry ice, 133 
thaw on ice, and wash as required with ice cold 1xPBS (for details on tissues 134 
and PBS washes, see Table 1). Avoid unnecessary freeze-thaw cycles as this 135 
will affect protein quality.  136 
1.1.2. Add radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl 137 
(pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) 138 
containing 1x protease inhibitor to each sample, using the optimal amount 139 
per tissue weight (see Table 1 for recommendations).  140 
NOTE: Depending on the application, the type and amount of 141 
homogenization buffer may need further optimization.  142 
1.1.3. Use a hand-held electric homogenizer with a polypropylene pestle to 143 
homogenize tissue samples. Between each sample wash the pestle in double-144 
distilled water and dry with a clean tissue. Change the pestle between 145 
different experimental conditions and tissues. 146 
1.1.4. Leave the samples on ice for 10 minutes after homogenization. 147 
Centrifuge the samples at >10,000 x g at 4°C for 10 minutes.  148 
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1.1.5. Transfer the supernatant to a new tube on ice without disturbing the 149 
pellet. The supernatant is the protein sample. Store the extracted protein at -150 
80°C or directly proceed to measuring the protein concentration. 151 
1.2.  Quantification and normalization of protein concentration   152 
1.2.1. Measure the protein concentration using a bicinchoninic acid (BCA) 153 
assay. Prepare a BCA assay mix according to the manufacturer’s instructions 154 
in a 96-well optical plate using 200 µL of BCA mix per well.  155 
NOTE: Other quantification methods such as Lowry and Bradford assays can 156 
also be used to determine protein concentration as long as protein 157 
concentration is quantified consistently across experiments.  158 
1.2.2. Prepare bovine serum albumin (BSA) standards at increasing 159 
concentrations in triplicate and add 1 µL of each protein sample in duplicate. 160 
Incubate the 96-well plate in a preheated heat block at 60°C for 10 minutes 161 
or longer if the protein concentration is expected to be low.   162 
1.2.3. After incubation, measure the absorption at 560 nm using a plate 163 
reader. 164 
1.2.4. Export the plate reader measurements and calculate the protein 165 
concentration by comparing the average absorbance values of each sample 166 
to a standard curve obtained using the protein standard. The R-squared 167 
value for the standard curve should be greater than or equal to 0.98 to 168 
accurately estimate sample protein concentration.  169 
1.2.5. Normalize the amount of protein by preparing dilutions of protein 170 
samples in sample buffer and ultrapure water. The total volume can be 171 
adjusted depending on the type of gel used. Loading 30 µg of protein per 172 
lane as a starting amount is recommended. Add reducing agent such as 173 
dithiothreitol (DTT; final concentration 5 mM) or beta-mercaptoethanol (final 174 
concentration 200 mM) to each sample as required. Pipette undiluted beta-175 
mercaptoethanol in a fume hood.  176 
1.2.6. Incubate the samples in a heat block at 70°C for 10 minutes. Put the 177 
samples on ice, vortex and spin down briefly to collect. Keep on ice until 178 
loading the gel.  179 
 180 
2. Gel electrophoresis of protein samples 181 
2.1. Device and gel set up 182 
2.1.1. Setup a precast 4–12% Bis-Tris gradient gel (see Table of Materials) 183 
in the gel electrophoresis chamber system. Rinse gels using double-distilled 184 
water before use.  185 
NOTE: Depending on the size, interactions and abundance of the protein 186 
   
Page 5 of 13   
 
of interest, gels with a different gradient, buffering agent or well size and 187 
number can be used.  188 
2.1.2. Add 500 mL of 1x MES SDS running buffer diluted in double-distilled 189 
water per tank. Carefully remove the comb from the gels after adding the 190 
running buffer without disturbing the wells in the stacking gel. 191 
2.2.  Protein loading 192 
2.2.1. Load 3.5 µL of a protein standard into the well. Depending on the 193 
sample layout, loading a protein ladder on both sides of the gel can aid in 194 
more accurately estimating protein size. Use fine-tipped gel loading tips for 195 
more accurate sample loading.  196 
2.2.2. When using an internal standard for between-membrane 197 
normalization (see step 5 below and Discussion), load an amount that is 198 
equal to the other samples into the first 3 wells next to the protein ladder. 199 
2.2.3. Load 30 µg of each sample in the remaining wells. Add 1x sample 200 
buffer to all empty wells.  201 
2.3. Electrophoresis 202 
2.3.1. Assemble the gel tank after loading the samples. Run the samples 203 
through the stacking gel at 80V for 10 minutes followed by 150 V for an 204 
additional 45-60 mins. 205 
 206 
3. Protein transfer  207 
Protein transfer in this protocol is performed using a commercially available semi-dry blotting 208 
system (see Table of Materials) for fast and consistent outcomes.  209 
3.1. Prepare protein transfer by pre-soaking filter paper in double-distilled water 210 
and making  sure the gel knife, plastic Pasteur pipette, blotting roller and forceps are 211 
ready to use.  212 
3.2. Open the transfer stack by carefully removing all wrapping foil. Remove the top 213 
from the bottom stack and set it aside.  Quickly moisten the membrane on the 214 
bottom stack with several drops of electrophoresis running buffer (2-3 mL). Once 215 
the transfer stack is open, it is important to prevent the PVDF membrane from 216 
drying out. 217 
3.3. After stopping the electrophoresis, open the pre-cast gel using the gel knife and 218 
cut off the stacking gel. Cut the gel around its edges to free it from the plastic cast. 219 
Keep the gel knife wet to prevent damage to the gel.  220 
3.4. Assemble the transfer stack from bottom to top: bottom stack (containing the 221 
PVDF membrane), protein gel, filter paper. Use the blotting roller to remove all air 222 
bubbles. Place the top stack on top of the filter paper and roll the stack again to 223 
remove air bubbles. Do not push too strongly as this may cause the gel to deform 224 
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during protein transfer.  225 
3.5. Transfer the whole stack into the transfer device with the electrode on the left 226 
side of the device and place the gel sponge on top of the stack so that it is aligned 227 
with the corresponding electrical contacts on the device. Close the lid, select and 228 
start the appropriate program (20V for 7 minutes is a recommended starting point).   229 
3.6. When finished, leave the lid closed for two minutes to allow the stack to cool 230 
down and to prevent the membrane from drying out. Remove the transfer stack and 231 
cut the membrane to the gel size. Wash the cut membrane quickly with double-232 
distilled water before continuing with the total protein stain.    233 
 234 
4. Total protein staining 235 
Using fluorescent detection provides a substantial benefit over more traditional approaches 236 
(e.g. ECL detection), as the linear range and sensitivity can be much better controlled4. 237 
Therefore, in steps 4 and 5 a fluorescent TPS and fluorescent secondary antibodies are used 238 
(see Table of Materials).  239 
4.1. Roll the membrane into a 50-mL tube with the protein side facing inwards. 240 
Because of light sensitivity of the fluorescent TPS and secondary antibodies, all 241 
subsequent steps are carried out in the dark. 242 
4.2. Add 5mL of protein stain solution (see Table of Materials) and incubate on a 243 
roller for 5 minutes at room temperature. Because TPS and wash buffer contain 244 
methanol carry these steps out in a fume hood.  245 
4.3. Discard the staining solution and wash twice quickly with the 5mL wash solution 246 
(6.3% acetic acid in 30% methanol). Place the tube briefly back on the roller between 247 
wash steps. Rinse the membrane briefly with MilliQ water before continuing. 248 
 249 
5. Blocking, antibody incubation and detection  250 
5.1.  Blocking the membrane 251 
Add 3 mL of blocking buffer (see Table of Materials) to the 50 mL tube 252 
containing the membrane. Incubate the membrane on a roller for 30 minutes at 253 
room temperature. Depending on the choice of antibody, the type of blocking 254 
buffer used may require optimization.  255 
5.2.  Primary antibody incubation 256 
5.2.1. Discard the blocking buffer and replace with the primary antibody at 257 
the appropriate, optimized concentration (Figure 1 and Figure 2: mouse-anti-258 
SMN, at 1:1000, diluted in blocking buffer).  259 
NOTE: Adequate optimization of primary antibodies should include 260 
confirmation that the antibody detects a protein product of the right size 261 
whilst showing no or minimal binding to other, unspecific protein products. If 262 
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possible, test and compare multiple antibodies against the protein of interest.  263 
5.2.2. Incubate the membrane on a roller overnight at 4°C. The next day, 264 
remove the antibody solution and wash 6 times 5 minutes with 1x PBS on a 265 
roller at room temperature (RT). 266 
5.3. Secondary antibody incubation 267 
5.3.1. Prepare the specific secondary antibody at 1:5,000 against the host of 268 
the primary antibody in 5 mL blocking buffer. Other secondary antibodies 269 
may require other dilutions or the use of alternative blocking buffers.  270 
5.3.2. Incubate the membrane with the secondary antibody solution on a 271 
roller for one hour at RT. After incubation, wash the membrane three times 272 
30 minutes with 1x PBS on a roller. 273 
5.3.3. Dry the membrane and keep the membrane protected from light 274 
using aluminum foil until detection. Membranes can be kept at 4°C for long 275 
term storage. 276 
5.4.  Image acquisition 277 
5.4.1. Login to the computer attached to the scanner. Place the membrane 278 
on the scanner with the protein side facing down and select the scanning 279 
area in the software. 280 
5.4.2. Optimize the laser intensity for both (700nm and 800nm) channels, 281 
by confirming no saturation occurs. Acquire the images in both channels and 282 
export the images for further analysis (see below).  283 
 284 
6. Western blot analysis and quantification 285 
These recommendations are based on the freely available Image Studio software. However, 286 
comparable analyses can also be done using other software packages, such as ImageJ.  287 
6.1. Import the file 288 
Create a local workspace on the computer used for analysis. This generates a 289 
database of image files for acquired western blots. Import files obtained on the 290 
scanner and select the image for analysis.  291 
6.2. TPS analysis 292 
6.2.1. Display the 700nm channel to show the total protein staining result. 293 
An example of a TPS image is included in Figure 1 in which different tissues 294 
from neonatal (P5) (Figure 1A-B) and 10-week old mice (Figure 1C-D) are 295 
compared directly. Similarly, Figure 2 shows an example of a direct 296 
comparison of brain tissue from mice of different ages.  297 
6.2.2. Select “Analysis” tab from top right corner and select “Add 298 
Rectangle” to define the area of interest for normalization (as illustrated in 299 
Figure 1B and 1D). Copy and paste the first rectangle area onto each 300 
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individual sample to ensure the defined region is at the same size for all 301 
analyzed lanes.  302 
6.2.3. Copy the result from the “Shapes” tab in the bottom left corner of 303 
the software.   304 
6.3. Quantification 305 
The optimal approach for quantifying samples depends on the experimental 306 
design. We will here provide an illustrative example of the detection of the 307 
survival motor neuron protein (Smn; a key protein involved in the 308 
neuromuscular disease spinal muscular atrophy20,21), that is known to decrease 309 
over time19 and how normalization of Smn signal intensity to TPS provides 310 
reliable estimates of protein expression development.  311 
6.3.1. Figure 2 shows a decrease of Smn expression with increasing age of 312 
the animal with TPS as protein loading control. Repeat Step 6.2.1-6.2.3 to 313 
quantify protein loading (Figure 2B). Repeat Step 6.2.1-6.2.3 in the 800nm 314 
channel (Figure 2A) to analyze the protein of interest. 315 
6.3.2. Copy the results from both TPS and protein of interest to a 316 
spreadsheet program. On the spreadsheet, first normalize the protein 317 
loading by determining the highest TPS signal and and dividing each TPS 318 
signal value by this value to obtain the normalized protein loading value.   319 
6.3.3. Divide the 800nm signal value from each individual sample by its 320 
corresponding normalized protein value to calculate the relative protein 321 
expression ratio in different samples. 322 
6.3.4. After the first normalization, various time points or tissues can be 323 
compared to the average value of the internal standard to allow direct 324 
comparisons across different membranes and experiments.  325 
 326 
7. Statistics 327 
To determine any statistically significant differences in protein expression across complex and 328 
large groups of samples, appropriate statistical methodology is required. Although a detailed 329 
discussion of statistical background goes beyond the scope of this paper, we want to highlight 330 
several considerations and detail a successful approach that we have used previously19.  331 
 As for many experiments, protein quantification measurements do not represent 332 
completely independent data. Here, for example, multiple tissues are generally obtained from 333 
single animals to determine protein levels across multiple organs at a single experimental time-334 
point. Therefore, we used a mixed effects models to analyze differences in protein expression 335 
over time, and between tissues.  In general, mixed effects models provide an effective means to 336 
deal with non-independence and thereby avoid pseudo-replication22,23. In the present case, 337 
mixed effects models increase statistical power by accounting for repeated measurements 338 
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among tissues, within individuals. We use the statistical software package R to perform these 339 
analyses, as this is freely available and versatile. However, other commercially available 340 
packages may be able to perform similar analyses.   341 
The current experimental design involves a “split plot” design because each mouse 342 
belonged to only one age group. Therefore, we modeled individual mice (mouse ID) as a 343 
random effect with a unique identifier; we also accounted for tissue, age, and their interaction 344 
as fixed effects. We modeled the data using the function lmer in the R library, lme4. As a quality 345 
control step, we visualized residuals to assess the assumptions of equal variance and a normal 346 
distribution and transformed the data where necessary to meet these assumptions. To test for 347 
a significant interaction between tissue and age, we fit an identical model that lacked this 348 
interaction, and compared the models using parametric bootstrapping (R function PBmodcomp 349 
in the library, pbkrtest).  Where significant interactions arose, we used the function emmeans 350 
(in the emmeans R library) to determine the cause of the interaction.  For example, we 351 
compared mean expression among age classes within each tissue; a significant interaction may 352 
arise between age and tissue if, say, two given age classes differed significantly for one tissue 353 
but not another. In summary, these approaches provide a way to extend the robustness of 354 
conclusions from western blot experiments by providing statistical support to these results.  355 
 356 
REPRESENTATIVE RESULTS: 357 
We include examples of the use of TPS and an internal standard to facilitate comparisons of 358 
protein levels across tissues and time points. Figure 1 shows results from western blotting on 359 
protein extracted from tissues obtained from neonatal (postnatal day 5) in comparison to adult 360 
mice (10-week old). TPS and Smn immunoblot are shown in Figure 1A and 1C. Quantification of 361 
fluorescence intensity of the TPS was achieved by measuring the fluorescence intensity inside 362 
the rectangle box on each lane and its results are shown in the tables in Figure 1B and 1D. Note 363 
that samples from different tissues are characterized by different TPS protein band patterns 364 
and therefore it is necessary to use the whole lane for normalization purposes. Indeed, when 365 
whole lanes are analysed, the fluorescence intensity remains relatively similar across samples, 366 
indicating TPS for normalization is suitable for this purpose. An internal standard consisting of a 367 
P5 brain lysate mixture was also included to illustrate how it can be used for further 368 
comparisons between different membranes. Furthermore, in Figure 2 we show how a 369 
fluorescent TPS can be used to compare protein levels at different developmental time points. 370 
Here, we show Smn levels in brain lysates from neonatal (P5), weaning age (P20) and adult 371 
(10W) mice (Figure 2A). Although Smn levels clearly decrease with age, TPS quantification 372 
remains constant as illustrated in Figure 2B.  373 
 374 
FIGURE AND TABLE LEGENDS: 375 
Figure 1. Western blots showing TPS and Smn protein levels in mouse tissues at two different 376 
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ages. (A,C) TPS and Smn protein for P5 (A) and 10 week-old (C) mice. (B,D) The fluorescence 377 
intensity of whole-lane TPS was calculated and is indicated (in arbitrary units). M: marker / 378 
protein standard; kDa: kilodalton; a.u.: arbitrary unit; P5: postnatal day 5; 10W: 10 weeks.  379 
Figure 2. Analysis of Smn expression in mouse tissues at different developmental time points. 380 
(A) Brain lysates from tissue obtained from P5, P20 and 10 week-old mice was analyzed using 381 
TPS (top panel) and SMN (bottom panel). (B) The fluorescence intensity of the TPS was 382 
calculated and is indicated in arbitrary units. M: marker / protein standard; kDa: kilodalton; 383 
a.u.: arbitrary unit; P5: postnatal day 5; P20: postnatal day 20; 10W: 10 weeks. 384 
Table 1. Overview of expected tissues weights and corresponding recommendations for PBS 385 
washes and lysis buffer volume to be used for homogenization. The weights are indications for 386 
tissue obtained from postnatal day 8 (P8) mice. PBS and lysis buffer volumes can be scaled up 387 
and down according to experimental needs.  388 
Table of Materials. Overview of suggested commercially available reagents, equipment, 389 
consumable and software used for the western blot analyses described in this protocol.   390 
 391 
DISCUSSION: 392 
With the appropriate experimental design, control measures and statistical analysis, western 393 
blotting can be used to make reliable quantitative estimates of protein expression within and 394 
between a varied range of biological samples. The protocol we describe in the current 395 
manuscript aims to serve as a guideline for researchers looking to use western blotting to 396 
undertake quantitative analysis across larger and more complex groups of samples, by using a 397 
combination of fluorescence-based detection methods, total protein loading normalization and 398 
internal standards. Although the focus here is on determining and comparing protein 399 
expression from different mouse tissues and at different ages, this approach can also be 400 
extended to compare protein expression in other experimental conditions.  401 
A central step in our current protocol is the normalization of proteins of interest to total 402 
protein loaded by quantifying a fluorescent total protein stain. TPS normalization corrects for 403 
variation in sample loading and error margins in protein quantification methods. However, 404 
because the number of protein samples that can be analyzed on a single membrane is often 405 
limited, further normalization may be required to compare multiple membranes. Indeed, 406 
variability between how proteins are detected on different membranes (due to for example 407 
antibody incubation time or temperature variation) may cause variation beyond that 408 
introduced through loading and quantification steps of the protocol. Here, we use an internal 409 
standard that consists of a single protein lysate mix that is loaded in triplicate on each gel and 410 
allows for comparison and normalization between gels/membranes. Theoretically this could be 411 
any protein sample, as long as it can be made in sufficient quantities so that the same sample 412 
can be used for all experiments. In our experiments we use a mixture of brain protein lysates, 413 
as brain homogenates contain large quantities of protein and are typically obtained at a high 414 
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concentration. Averaging quantification of triplicate standard should further increase the 415 
accuracy of quantifications across membranes and contribute to the reproducibility of the 416 
experiment.  417 
Protein levels can be determined by a number of different techniques and the preferred 418 
method depends on the sample type being analyzed and the goal of the experiment. 419 
Reproducible quantification of western blot works best in situations where experimental 420 
conditions can be well-controlled, such as when using mouse or other animal models of a 421 
defined genetic background. In contrast, in many experiments using human patient samples 422 
this may be less feasible as age, genetic variability and tissue sampling times are much harder 423 
to control than in (animal) model systems. Plate-based techniques such as ELISA might be more 424 
suitable for these analyses, although the careful validation of antibody specificity is crucial. For 425 
example, in fragile X syndrome research, antibodies have been shown to detect different 426 
isoforms and when used in ELISA this would lead to overestimation of the total amount of 427 
protein as ELISA determines a signal for all isoforms combined24. Optimal choices for methods 428 
to determine protein expression are therefore depending on context, sample type and the 429 
research question that is being investigated.  430 
Performing adequate statistical analysis is a prerequisite for the reliability of any 431 
conclusions drawn from the quantification of biological data. Statistically analyzing complex 432 
data as generated by comparing different tissues, time points or other experimental conditions 433 
and combinations thereof may require more advanced statistical modelling than ANOVA with 434 
post-hoc testing can deliver. For more complex statistical modelling, such as the mixed-effects 435 
model approach we describe in the current manuscript, it may be advisable to seek further 436 
advise from biostatisticians. Adequate statistical analysis of large-scale protein expression can 437 
greatly improve the robustness of the outcomes and the reliability and reproducibility of 438 
results.  439 
In summary, the experimental approach we describe here provides a robust and 440 
reproducible method for researchers that want to determine protein expression using western 441 
blot in complex samples allowing to answer new and exciting research questions.  442 
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Table 1.
Tissue Approx. weight* 1xPBS wash (4 °C) Repeat wash Homogenizing buffer **
Spinal cord 40 mg 150 µL 3x 100 µL
Muscle (GC) 20 mg 150 µL 3x 100 µL
Brain 240 mg 400 µL 4x 400 µL
Heart 60 mg 400 µL 4x 200 µL
Liver 130 mg 400 µL 4x 400 µL
Kidney 45 mg 400 µL 4x 200 µL
* These weights are indicative values for tissue obtained from P8 mice.
** These volumes are indications and can be further adjusted according to the weight of the tissue.
Table of Materials.
Name of Material/ Equipment Company Catalog Number Comments/Description
Fine Tipped Gel Loading Tips Alpha Laboratories GL20057SNTL
Halt Protease Inhibitor Cocktail, EDTA-free 100x 5mL ThermoFisher Scientific 78437
Handheld homogeniser VWR Collection 431-0100
iBlot 2 Gel Transfer Device ThermoFisher Scientific IB21001
iBlot Transfer Stack, PVDF, regular size ThermoFisher Scientific IB401031
Image Studio Lite Licor N/A
Free download from 
https://www.licor.com/bio/products/software/image_studio_
lite/
IRDye 800CW secondary antibodies Licor -- Select appropriate secondary antibody that is specific against host of primary antibody.
Micro BCA Protein Assay Kit ThermoFisher Scientific 23235
Novex Sharp Pre-stained Protein Standard ThermoFisher Scientific LC5800
NuPAGE 4-12% Bis-Tris Protein Gels, 1.0 mm, 15-well ThermoFisher Scientific NP0323BOX
NuPAGE LDS Sample Buffer (4X) ThermoFisher Scientific NP0007
NuPAGE MOPS SDS Running Buffer (20X) ThermoFisher Scientific NP0001
Odyssey Blocking Buffer Licor 927-40000
Purified Mouse anti-SMN (survival motor neuron) monoclonal antibody BD Transduction Laboratories 610646 Is used extensively in the SMN/SMA literature and gives consistent results regardsless of lot number
REVERT Total Protein Stain, 250 mL Licor 926-11021 
REVERT Wash Solution Licor 926-11012 
RIPA Lysis and Extraction Buffer ThermoFisher Scientific 89900
XCell SureLock Mini-Cell ThermoFisher Scientific EI0001
